149 related articles for article (PubMed ID: 22803688)
1. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
Bain G; King CD; Schaab K; Rewolinski M; Norris V; Ambery C; Bentley J; Yamada M; Santini AM; van de Wetering de Rooij J; Stock N; Zunic J; Hutchinson JH; Evans JF
Br J Clin Pharmacol; 2013 Mar; 75(3):779-90. PubMed ID: 22803688
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study.
Follows RM; Snowise NG; Ho SY; Ambery CL; Smart K; McQuade BA
Respir Res; 2013 May; 14(1):54. PubMed ID: 23682661
[TBL] [Abstract][Full Text] [Related]
3. The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma.
Kent SE; Boyce M; Diamant Z; Singh D; O'Connor BJ; Saggu PS; Norris V
Clin Exp Allergy; 2013 Feb; 43(2):177-86. PubMed ID: 23331559
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Bain G; King CD; Rewolinski M; Schaab K; Santini AM; Shapiro D; Moran M; van de Wetering de Rooij S; Roffel AF; Schuilenga-Hut P; Milne GL; Lorrain DS; Li Y; Arruda JM; Hutchinson JH; Prasit P; Evans JF
Clin Pharmacol Ther; 2010 Apr; 87(4):437-44. PubMed ID: 20182424
[TBL] [Abstract][Full Text] [Related]
5. Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.
Ericsson H; Nelander K; Lagerstrom-Fermer M; Balendran C; Bhat M; Chialda L; Gan LM; Heijer M; Kjaer M; Lambert J; Lindstedt EL; Forsberg GB; Whatling C; Skrtic S
Clin Transl Sci; 2018 May; 11(3):330-338. PubMed ID: 29517132
[TBL] [Abstract][Full Text] [Related]
6. Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils.
Chaudhuri R; Norris V; Kelly K; Zhu CQ; Ambery C; Lafferty J; Cameron E; Thomson NC
Pulm Pharmacol Ther; 2014 Feb; 27(1):62-9. PubMed ID: 24333186
[TBL] [Abstract][Full Text] [Related]
7. The effect of GSK2190915, a 5-lipoxygenase-activating protein inhibitor, on exercise-induced bronchoconstriction.
Kent SE; Bentley JH; Miller D; Sterling R; Menendez R; Tarpay M; Pearlman DS; Norris V
Allergy Asthma Proc; 2014; 35(2):126-33. PubMed ID: 24717789
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Uematsu T; Kanamaru M; Kosuge K; Hara K; Uchiyama N; Takenaga N; Tanaka W; Friedman BS; Nakashima M
Br J Clin Pharmacol; 1995 Jul; 40(1):59-66. PubMed ID: 8527269
[TBL] [Abstract][Full Text] [Related]
9. Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor.
Mosteller M; Condreay LD; Harris EC; Ambery C; Beerahee M; Ghosh S
Pharmacogenet Genomics; 2014 Dec; 24(12):618-21. PubMed ID: 25192553
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.
Depré M; Friedman B; Van Hecken A; de Lepeleire I; Tanaka W; Dallob A; Shingo S; Porras A; Lin C; de Schepper PJ
Clin Pharmacol Ther; 1994 Jul; 56(1):22-30. PubMed ID: 8033491
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
12. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
Stock NS; Bain G; Zunic J; Li Y; Ziff J; Roppe J; Santini A; Darlington J; Prodanovich P; King CD; Baccei C; Lee C; Rong H; Chapman C; Broadhead A; Lorrain D; Correa L; Hutchinson JH; Evans JF; Prasit P
J Med Chem; 2011 Dec; 54(23):8013-29. PubMed ID: 22059882
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
Knöchel J; Nelander K; Heijer M; Lindstedt EL; Forsberg GB; Whatling C; Shimada H; Han DS; Gabrielsen A; Garkaviy P; Ericsson H
Clin Drug Investig; 2021 Oct; 41(10):895-905. PubMed ID: 34546534
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose-response study.
Singh D; Boyce M; Norris V; Kent SE; Bentley JH
Int J Gen Med; 2013; 6():897-903. PubMed ID: 24357936
[TBL] [Abstract][Full Text] [Related]
16. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.
Depre M; Friedman B; Tanaka W; Van Hecken A; Buntinx A; DeSchepper PJ
Clin Pharmacol Ther; 1993 May; 53(5):602-7. PubMed ID: 8387904
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.
Depré M; Van Hecken A; Verbesselt R; De Lepeleire I; Schwartz J; Porras A; Larson P; Lin C; De Schepper PJ
Int J Clin Pharmacol Res; 1998; 18(2):53-61. PubMed ID: 9675622
[TBL] [Abstract][Full Text] [Related]
19. Addition of a 5-lipoxygenase-activating protein inhibitor to an inhaled corticosteroid (ICS) or an ICS/long-acting beta-2-agonist combination in subjects with asthma.
Snowise NG; Clements D; Ho SY; Follows RM
Curr Med Res Opin; 2013 Dec; 29(12):1663-74. PubMed ID: 24010736
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
